Charles Schwab
ARCT icon

Charles Schwab’s Arcturus Therapeutics ARCT Stock Holding History

Charles Schwab’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.56M Buy
231,628
+15,128
+7% +$119K ﹤0.01% 2868
2026
Q1 		$1.67M Buy
216,500
+32,645
+18% +$238K ﹤0.01% 2763
2025
Q4 		$1.13M Sell
183,855
-25,601
-12% -$276K ﹤0.01% 2888
2025
Q3 		$3.86M Buy
209,456
+19,379
+10% +$311K ﹤0.01% 2540
2025
Q2 		$2.47M Sell
190,077
-4,552
-2% -$53.8K ﹤0.01% 2603
2025
Q1 		$2.06M Sell
194,629
-13,173
-6% -$209K ﹤0.01% 2611
2024
Q4 		$3.53M Buy
207,802
+10,180
+5% +$192K ﹤0.01% 2498
2024
Q3 		$4.59M Buy
197,622
+3,224
+2% +$69K ﹤0.01% 2418
2024
Q2 		$4.73M Buy
194,398
+3,632
+2% +$110K ﹤0.01% 2382
2024
Q1 		$6.44M Buy
190,766
+4,456
+2% +$158K ﹤0.01% 2193
2023
Q4 		$5.87M Buy
186,310
+2,369
+1% +$56.3K ﹤0.01% 2236
2023
Q3 		$4.7M Buy
183,941
+5,435
+3% +$167K ﹤0.01% 2290
2023
Q2 		$5.12M Sell
178,506
-870
-0.5% -$23.7K ﹤0.01% 2230
2023
Q1 		$4.3M Buy
179,376
+825
+0.5% +$14.8K ﹤0.01% 2278
2022
Q4 		$3.03M Buy
178,551
+7,727
+5% +$135K ﹤0.01% 2434
2022
Q3 		$2.53M Buy
170,824
+14,566
+9% +$244K ﹤0.01% 2518
2022
Q2 		$2.46M Buy
156,258
+1,707
+1% +$33.5K ﹤0.01% 2500
2022
Q1 		$4.17M Buy
154,551
+3,704
+2% +$94.5K ﹤0.01% 2362
2021
Q4 		$5.58M Buy
150,847
+1,287
+0.9% +$52.4K ﹤0.01% 2298
2021
Q3 		$7.15M Buy
149,560
+4,939
+3% +$221K ﹤0.01% 2204
2021
Q2 		$4.89M Buy
144,621
+6,095
+4% +$206K ﹤0.01% 2367
2021
Q1 		$5.72M Buy
138,526
+2,696
+2% +$161K ﹤0.01% 2232
2020
Q4 		$5.89M Buy
135,830
+18,788
+16% +$1.27M ﹤0.01% 2140
2020
Q3 		$5.02M Buy
117,042
+83,449
+248% +$4.14M ﹤0.01% 2055
2020
Q2 		$1.57M Buy
+33,593
New +$1.16M ﹤0.01% 2499

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Charles Schwab's ARCT Position: Q2 2026 in Review

Charles Schwab increased its Arcturus Therapeutics (ARCT) stake by 7% in Q2 2026, buying an estimated $119K and bringing the position to 231,628 shares worth $1.56M. The position accounts for ﹤0.01% of the portfolio, ranked #2868.

Charles Schwab first reported a position in ARCT in Q2 2020 and has held it in 25 quarters since. The position peaked at $7.15M in Q3 2021. 136 funds tracked by Wall St. Rank hold ARCT as of Q2 2026.

  • Charles Schwab held 231,628 shares of Arcturus Therapeutics worth $1.56M as of Q2 2026.
  • Charles Schwab bought 15,128 Arcturus Therapeutics shares in Q2 2026, an estimated $119K.
  • Arcturus Therapeutics made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2868 holding.
  • Charles Schwab first reported a position in Arcturus Therapeutics in Q2 2020 and has held it in 25 quarters since.
  • Charles Schwab's Arcturus Therapeutics position peaked at $7.15M in Q3 2021.
  • 136 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.